Abiomed Inc. (NASDAQ:ABMD) CEO Michael R. Minogue sold 28,039 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $127.07, for a total value of $3,562,915.73. Following the completion of the sale, the chief executive officer now directly owns 215,488 shares in the company, valued at approximately $27,382,060.16. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Abiomed Inc. (NASDAQ:ABMD) opened at 123.53 on Friday. Abiomed Inc. has a 12 month low of $67.81 and a 12 month high of $127.86. The stock’s 50 day moving average price is $121.06 and its 200 day moving average price is $106.47. The firm has a market capitalization of $5.29 billion, a PE ratio of 131.41 and a beta of 0.89.
Abiomed (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.06. Abiomed had a return on equity of 11.86% and a net margin of 11.75%. The firm had revenue of $103 million for the quarter, compared to analyst estimates of $97.23 million. During the same period in the previous year, the company posted $0.20 earnings per share. The company’s quarterly revenue was up 40.3% compared to the same quarter last year. Equities research analysts expect that Abiomed Inc. will post $1.17 earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. Zacks Investment Research raised Abiomed from a “hold” rating to a “buy” rating and set a $138.00 price target on the stock in a report on Friday, September 16th. Jefferies Group reissued a “buy” rating and issued a $125.00 price target on shares of Abiomed in a report on Friday, June 10th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $115.59.
Institutional investors have recently modified their holdings of the stock. State Street Corp increased its stake in Abiomed by 56.3% in the first quarter. State Street Corp now owns 1,316,168 shares of the company’s stock worth $124,787,000 after buying an additional 474,209 shares during the last quarter. Renaissance Technologies LLC increased its stake in Abiomed by 152.5% in the first quarter. Renaissance Technologies LLC now owns 287,100 shares of the company’s stock worth $27,220,000 after buying an additional 173,400 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Abiomed by 2,409.7% in the second quarter. BNP Paribas Arbitrage SA now owns 16,062 shares of the company’s stock worth $1,755,000 after buying an additional 15,422 shares during the last quarter. GSA Capital Partners LLP increased its stake in Abiomed by 132.6% in the second quarter. GSA Capital Partners LLP now owns 18,051 shares of the company’s stock worth $1,973,000 after buying an additional 10,289 shares during the last quarter. Finally, Granahan Investment Management Inc. MA increased its stake in Abiomed by 11.6% in the first quarter. Granahan Investment Management Inc. MA now owns 322,383 shares of the company’s stock worth $30,565,000 after buying an additional 33,400 shares during the last quarter. Hedge funds and other institutional investors own 93.65% of the company’s stock.
Abiomed Company Profile
Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.